Coya Therapeutics, Inc. (COYA)
| Market Cap | 113.30M +11.1% |
| Revenue (ttm) | 8.02M +1,793.8% |
| Net Income | -21.67M |
| EPS | -1.09 |
| Shares Out | 23.46M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,155 |
| Open | 4.810 |
| Previous Close | 4.850 |
| Day's Range | 4.755 - 4.890 |
| 52-Week Range | 3.710 - 7.750 |
| Beta | 0.58 |
| Analysts | Strong Buy |
| Price Target | 15.21 (+214.91%) |
| Est. Earnings | Nov 11, 2026 |
About COYA
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatm... [Read more]
Financial Performance
In 2025, Coya Therapeutics's revenue was $7.95 million, an increase of 123.57% compared to the previous year's $3.55 million. Losses were -$21.23 million, 42.6% more than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for COYA stock is "Strong Buy." The 12-month stock price target is $15.21, which is an increase of 214.91% from the latest price.
News
Coya announces full enrollment in Phase 2/3 ALSTARs trial of COYA 302
Coya Therapeutics (COYA) announced full enrollment of the planned 120 participants in the Company’s Phase 2/3 ALSTARS Trial evaluating COYA 302, Coya’s combination of proprietary low-dose IL-2 and CTL...
Coya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in pa...
Coya Therapeutics announces 100th patient enrolled in Phase 2/3 ALSTARS trial
Coya Therapeutics (COYA) announced that the 100th patient has been enrolled in the Company’s ongoing Phase 2/3 ALSTARS Trial evaluating COYA 302, Coya’s combination of proprietary low-dose IL-2 and CT...
Coya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in pa...
Coya announces publication of preclinical study on effects of COYA 303
Coya Therapeutics (COYA) announced the publication of preclinical results for COYA 303 in the International Journal of Molecular Sciences. The article was published as part of the Special Issue, “The…
Coya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of COYA 303 in a Well-Established Model of Peripheral and CNS Inflammation
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, today announc...
Coya Therapeutics Slides: Investor presentation
Coya Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 1, 2026.
Coya Therapeutics reports Q2 EPS (28c), consensus (36c)
Reports Q2 revenue $243.7k, consensus $104.29k. “During the second quarter, we made notable progress advancing our lead program, COYA 302,” said Arun Swaminathan, Ph.D., Chief Executive Officer of Coy...
Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in pa...
Coya Therapeutics Quarterly report: Q2 2026
Coya Therapeutics has published its Q2 2026 quarterly earnings report on August 11, 2026.
Coya Therapeutics Earnings release: Q2 2026
Coya Therapeutics released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Coya Therapeutics Slides: Investor presentation
Coya Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 7, 2026.
Coya Therapeutics Slides: Investor presentation
Coya Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 29, 2026.
Coya Therapeutics Transcript: AGM 2026
The meeting covered board elections, ratification of auditors, and strategic updates on clinical programs for neurodegenerative diseases. Financials showed a strong cash position and non-dilutive funding. All proposals passed, and no questions were raised during the Q&A.
Coya Therapeutics Transcript: Investor update
Concussion awareness has evolved, with protocols now addressing both diagnosed and subconcussive impacts. Inflammation is central to brain injury and neurodegeneration, driving new therapies and prevention strategies. Collaboration and funding are essential for advancing research and protecting athletes' long-term health.
Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in pa...
Coya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in pa...
Coya Therapeutics initiates first cohort of patients in ALSTARS trial
Coya Therapeutics (COYA) announces the initiation of the blinded extension phase of the ALSTARS Trial. Patients who complete the 24-week placebo-controlled double-blind phase enter the blinded extensi...
Coya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension Phase
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces the...
Coya Therapeutics initiated with a Buy at Roth Capital
Roth Capital initiated coverage of Coya Therapeutics (COYA) with a Buy rating and $12 price target The firm says its bullish view is predicated on COYA 302’s positive Phase 1…
Coya Therapeutics Slides: Investor presentation
Coya Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 1, 2026.
Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in pa...
Coya Therapeutics Proxy statement: Proxy filing
Coya Therapeutics filed a proxy statement on May 13, 2026, providing details for shareholder voting and corporate governance matters.
Coya Therapeutics Proxy statement: Proxy filing
Coya Therapeutics filed a proxy statement on May 13, 2026, providing details for shareholder voting and corporate governance matters.
Coya Therapeutics granted FDA Fast Track Designation for COYA 302
Coya Therapeutics (COYA) announced that the U.S. Food and Drug Administration has granted Fast Track Designation for COYA 302, a proprietary investigational biologic combination therapy with a dual me...